A study has reported that the MEK inhibitor trametinib reduced the risk of disease progression or death by 52% compared to standard-of-care therapies for the treatment of low-grade serous ovarian carcinoma.
Click here for original story, Trametinib represents potential new standard-of-care for patients with recurrent low-grade serous ovarian carcinoma
Source: ScienceDaily